The reactivities were compared for 5-iodo-2-methylthio-6-methyl(trifluoromethyl)pyrimidin-4(3H)-ones and their 4-methoxylated derivatives in the Suzuki-Miyaura cross-coupling reactions. The iodopyrimidinones were shown to be poorly involved in these reactions, since the target 5-arylpyrimidinones (5 examples) were obtained in low yield (<35%). For the first time, it has been established that the presence of the acidic NH proton of the lactam fragment is the reason for the low reactivity of pyrimidin-4-ones; with the involvement of this fragment, the formation of salts and palladium complexes occurs, leading to the removal of substrates and the Pd catalyst from the catalytic cycle. In contrast, 5-iodo-4-methoxy-2-methylthio-6-methyl(trifluoromethyl)pyrimidines readily undergo cross-coupling to form 5-arylpyrimidines (11 examples). The best yields were achieved by using the Pd2(dba)3/XPhos catalytic system. Demethylation with 33 wt % HBr allowed 5-arylpyrimidin-4-ones to be obtained in overall yield higher than those with direct cross-coupling. Using biological testing, it was shown that introducing an aryl substituent at the C5 position of the pyrimidines promotes antimicrobial and antitumor activity.
Melnikov et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: